Inspire Pharmaceuticals, Inc.

Parion Sciences, Inc.

Aerie Pharmaceuticals, Inc.

Nicox Ophthalmics, Inc.

Allergan, Inc.

Tomas Navratil

Michael Ross Johnson

Richard C Boucher

Benjamin Maynor

Ward M Peterson

John W Lampe

William Robert Thelin

Emilee H Fulcher

Brian Button

Sanjib Kumar Das

Rozemarijn Verhoeven

Melissa Sandahl

Janet Tully

Stuart Williams

Scott D Sorensen

James B Fink

Anthony James Hickey

José L Boyer

Jessie Delgado

Mark Jeffrey Edhouse

Philip Jerome Driver

Brigitte Duquesroix-Chakroun

Stuart Robert Abercrombie

Akshay Nadkarni

Jonathan Hugh Wilkins

Donal Joseph Taylor

Nicholas O Heijne

Paul Boucher

Michael Hunter

Jean-Michel Bukowski

Benjamin Robinson Yerxa

Brian M Button

William R Thelin

Andres Garcia

A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Intravitreal drug delivery systems for the treatment of ocular conditions

Embodiments described herein relate generally to medical implant delivery apparatuses and methods. In some embodiments, an apparatus comprises a first cap, a needle hub at least partially disposed within the first cap, a pusher wire and a pusher wire connector disposed within the needle hub, a needle and a second cap. The first cap includes a proximal end, a distal end, and a longitudinal axis. The needle includes a first, beveled end configured to receive an implant, and a second end disposed within a hub pocket of the needle hub. The second cap is connected to the needle hub and disposed at a proximal end of the first cap. The pusher wire, the pusher wire connector, and the needle are substantially aligned with one another along the longitudinal axis of the first cap. In some embodiments, the pusher wire is sized to be received in the bore of the needle.

Implant applicators and methods of administering implants

Embodiments disclosed herein are directed to methods, compositions and apparatus for administering active agents to the lungs of a subject.

Methods of treatment

An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Aerosol delivery systems, compositions and methods

The present invention concerns methods, compositions and apparatus for administering active agents to the lungs of a subject.

This invention is directed to methods of preventing or treating diseases or conditions associated with alterations in cellular integrity including alterations in endothelial permeability, excessive cell proliferation or tissue remodeling. Particularly, this invention is directed to methods of treating diabetic nephropathy, malaria, or cancer. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease.

Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds

This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.

Method for treating pulmonary diseases using rho kinase inhibitor compounds

This invention is directed to methods of preventing or treating neurological or neuropathic diseases or conditions associated with excessive inflammation, neurodegeneration, neuro-remodeling, and axonal/neurite retraction. Particularly, this invention relates to methods treating neurological or neuropathic diseases such as cerebral ischemia, stroke, neuropathic pain, spinal cord injury, Alzheimer's disease, and multiple sclerosis, using novel rho kinase inhibitor compounds. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease.

Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds

Growing community of inventors

Carrboro, NC, United States of America

Tomas Navratil